Needham & Company LLC Raises GH Research (NASDAQ:GHRS) Price Target to $32.00

GH Research (NASDAQ:GHRS) had its target price hoisted by Needham & Company LLC from $31.00 to $32.00 in a report issued on Friday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price indicates a potential upside of 100.88% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Canaccord Genuity Group raised their price target on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Royal Bank Of Canada raised their target price on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. HC Wainwright lifted their price target on shares of GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of GH Research in a research report on Monday, January 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GH Research currently has an average rating of “Moderate Buy” and a consensus price target of $39.50.

GH Research Stock Performance

GH Research stock opened at $15.93 on Friday. The company has a market capitalization of $828.84 million, a PE ratio of -19.91 and a beta of 1.00. The company has a 50 day moving average price of $15.45 and a 200-day moving average price of $14.25. GH Research has a fifty-two week low of $7.98 and a fifty-two week high of $19.51.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.06. On average, analysts forecast that GH Research will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stempoint Capital LP acquired a new stake in shares of GH Research during the 2nd quarter worth approximately $1,229,000. CenterBook Partners LP purchased a new stake in GH Research during the third quarter worth $2,376,000. Virtus Investment Advisers LLC acquired a new stake in GH Research during the second quarter valued at $89,000. HighVista Strategies LLC acquired a new stake in GH Research during the second quarter valued at $637,000. Finally, Boothbay Fund Management LLC increased its holdings in GH Research by 504.0% in the third quarter. Boothbay Fund Management LLC now owns 83,550 shares of the company’s stock valued at $1,195,000 after buying an additional 69,717 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research News Roundup

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company business update — GH Research reported full‑year 2025 results and said it completed the Phase 2b GH001 trial in treatment‑resistant depression, presented the dataset at major conferences, and received FDA clearance to begin U.S. clinical investigations; the company also reported cash and marketable securities of $280.7M, which supports upcoming development programs. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly beat — GH Research reported EPS of ($0.23) vs. consensus ($0.29), surprising modestly to the upside, which likely helped lift sentiment. Quarterly press release
• Positive Sentiment: Analyst price‑target upgrades — Citizens JMP raised its target to $42 with a “market outperform” rating and Needham raised its target to $32 with a “buy” rating; separate coverage also shows a $70 target reported in the market press (HC Wainwright). These upgrades increase upside expectations and likely contributed to buying interest. Analyst upgrades (Benzinga) Needham PT raise Price target to $70 note
• Neutral Sentiment: Market commentary — Coverage noting GHRS activity across Nasdaq futures and broader market focus may amplify volatility but is not specific new corporate information. Kalkine Media article
• Neutral Sentiment: Short interest data appears non‑informative in recent reporting (shows 0 shares), so it does not appear to be a driver of current price action. (Reported days‑to‑cover is 0.0.)
• Negative Sentiment: HC Wainwright earnings revisions — Although HC Wainwright retains a “Buy” rating and a $70 target, the firm reduced near‑term EPS forecasts for FY2025–FY2028 (more negative near‑term EPS path), which introduces risk around timing and magnitude of commercialization and could temper upside. HC Wainwright comments

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.